Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Gross Profit (2022 - 2025)

TriSalus Life Sciences' Gross Profit history spans 4 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 62.43% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $38.2 million, up 50.77%, while the annual FY2025 figure was $38.2 million, 50.77% up from the prior year.
  • Gross Profit reached $11.4 million in Q4 2025 per TLSIW's latest filing, up from $9.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $11.4 million in Q4 2025 to a low of $2.3 million in Q1 2023.
  • Average Gross Profit over 4 years is $6.1 million, with a median of $5.9 million recorded in 2024.
  • The largest YoY upside for Gross Profit was 136.26% in 2024 against a maximum downside of 37.09% in 2024.
  • A 4-year view of Gross Profit shows it stood at $2.4 million in 2022, then soared by 113.24% to $5.1 million in 2023, then soared by 37.09% to $7.0 million in 2024, then surged by 62.43% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Gross Profit are $11.4 million (Q4 2025), $9.7 million (Q3 2025), and $9.4 million (Q2 2025).